44 -12 (86) 2025 - Elova H.R., Jabborova F.U. - CHEMOTHERAPY-INDUCED NEPHROTOXICITY AND ITS RELATIONSHIP WITH RENAL FAILURE

CHEMOTHERAPY-INDUCED NEPHROTOXICITY AND ITS RELATIONSHIP WITH RENAL FAILURE

Elova H.R. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Jabborova F.U. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Chemotherapeutic agents are essential in the treatment of malignant diseases, yet nephrotoxicity remains one of their most severe and frequent complications. Renal dysfunction leads to impaired drug elimination, increased systemic toxicity, treatment interruption, and overall worse prognosis. Platinum-based compounds, alkylating drugs, antimetabolites, targeted therapies, and immunotherapeutic agents are the most nephrotoxic groups. Clinical evidence shows that 30–50% of patients undergoing polychemotherapy develop acute or chronic kidney injury. This review summarizes the mechanisms of renal damage, risk factors, clinical manifestations, consequences on chemotherapy effectiveness, early biomarkers, and current preventive strategies. A deeper understanding of chemotherapy-induced nephrotoxicity is essential for improving treatment safety and preserving renal function in oncology patients.

Keywords: chemotherapy; nephrotoxicity; renal failure; platinum-based agents; tubular injury; acute kidney injury; biomarkers; targeted therapy; drug-induced kidney damage; oncology.

First page

250

Last page

252

For citation:Elova H.R., Jabborova F.U. - CHEMOTHERAPY-INDUCED NEPHROTOXICITY AND ITS RELATIONSHIP WITH RENAL FAILURE//New Day in Medicine 12(86)2025 250-252 https://newdayworldmedicine.com/en/new_day_medicine/12-86-2025

List of References

  1. Perazella M.A. Nephrotoxicity from Chemotherapeutic Agents. Kidney International. 2012;82(8):1231–1241.
  2. Rosner M.H., Jhaveri K.D. Onconephrology: The Intersections Between Cancer and Kidney Disease. Clinical Journal of the American Society of Nephrology. 2017;12(11):1791–1800.
  3. Kellum J.A. Acute Kidney Injury in the Cancer Patient. Critical Care Clinics. 2020;36(1):25–39.
  4. Shirali A.C., Perazella M.A. Tubulointerstitial Injury Associated with Chemotherapeutic Agents. Advances in Chronic Kidney Disease. 2014;21(1):56–65.
  5. Awdishu L., Joy M.S. Identification of Novel Biomarkers for Kidney Injury. Pharmacogenomics and Personalized Medicine. 2020;13:687–705.
  6. Hałka J., Spaleniak S., Kade G. The Nephrotoxicity of Drugs Used in Oncological Therapies. Current Oncology. 2022;29(12):9681–9694.
  7. Campbell G.A., Hu D., Okusa M.D. Acute Kidney Injury in the Cancer Patient. Advances in Chronic Kidney Disease. 2014;21(1):64–71.
  8. Finkel M., Goldstein A., Steinberg Y. Cisplatin Nephrotoxicity in Oncology Therapeutics. Pediatric Nephrology. 2014;29(12):2421–2424.
  9. Luciano R.L., Brewster U.C. Kidney Involvement in Leukemia and Lymphoma. Advances in Chronic Kidney Disease. 2014;21(1):27–35.
  10. Martinez-Castelao A., Gorriz J.L., Bover J. Consensus Document for Chronic Kidney Disease Management. Nefrologia. 2014;34(2):243–262.

    file

    download